
BIOMARIN PHARMACEUTICAL INC
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
BioMarin Pharmaceutical develops and sells treatments for rare genetic diseases, including enzyme replacement therapies for conditions like Hunter syndrome, Morquio A syndrome, and PKU, as well as a gene therapy for hemophilia A.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Friberg Gregory REVP, Chief R&D Officer | Sell | $303K | 5,147at $58.81 | Nov 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BMRN activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.